Gilead Sciences' Trodelvy in combination with Merck's blockbuster immunotherapy Keytruda lowered the risk of an aggressive ...

Combining pembrolizumab (Keytruda) with sacituzumab govitecan (SG, Trodelvy) instead of chemotherapy as first-line treatment ...

Keytruda shows a 35% reduced risk of disease progression or death against a type of aggressive breast cancer. Read more here.

Trodelvy, in combination with Merck’s immunotherapy Keytruda, lowered the risk of an aggressive type of breast cancer worsening by 35% when used as an initial treatment, according to new ...

Trodelvy, in combination with Keytruda, significantly lowers the risk of progression in triple-negative breast cancer by 35%, ...

In the control arm, 43% of patients crossed over to receive Trodelvy monotherapy after disease progression, representing 81% of those who received any subsequent treatment following chemo-Keytruda, ...

The use of Gilead’s Trodelvy and Merck’s Keytruda together could be practice-changing based on the results of a new study ...

In patients with first-line metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors, ...

Gilead Sciences, Inc. GILD announced positive top-line results from yet another late-stage study on breast cancer drug, ...

Two studies reveal promising treatments for breast cancer, enhancing options for patients with triple-negative breast cancer ...